Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Emery, GB
David Emery, Salisbury, GB
| Patent application number | Description | Published |
|---|---|---|
| 20110100745 | TUNABLE ACOUSTIC RELFECTOR - An acoustic reflector suitable for use as a reflective target for navigational aids and for location and re-location applications. The acoustic reflector comprises a shell arranged to surround a solid core. The shell is adapted to transmit acoustic waves incident thereon into the core. Within the core the acoustic waves are focused before being reflected from an opposing side of the shell to provide a reflected acoustic wave. The shell has at least two areas of transmissibility such that the waves incident on the shell follow separate paths within the core before being re-radiated and combining constructively to provide an enhanced reflected acoustic wave at one or more pre-determined frequencies. | 05-05-2011 |
David James Emery, Essex GB
| Patent application number | Description | Published |
|---|---|---|
| 20110241929 | HIGH FREQUENCY SURFACEWAVE RADAR - A process for reducing erroneous plots when detecting targets using High Frequency surfacewave radar (HFSWR) is provided. Detection of genuine targets is thereby enhanced. A first difference in range of an apparent target is determined, based on range data, associated with the apparent target. A second difference in range of the apparent target is determined, based on Doppler data, associated with the apparent target. The first and second range differences are compared to one another over time to assess a consistency therebetween. | 10-06-2011 |
Nigel Philip Emery, Buckinghamshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20090184053 | Water Treatment Method and Apparatus - A method of manufacturing a water treatment apparatus having one or more chambers comprising the step of: filling at least one chamber with ion exchanger resin; wherein at least one ion exchanger resin is dry. Preferably, the dry ion exchange resin has a water content of 0-40 wt %, preferably 0-20 wt %, and more preferably 0-10 wt %, such that the volume of the dry ion exchange resin is 25-50 vol % less than the volume of the same ion exchange resin in a moist or wetted form. One form of suitable water treatment apparatus is an EDI apparatus comprising a plurality of chambers to form a stack, for the purification of the water. The present invention provides an easier method of filling of chambers compared with the use of wetted or moist resins, and ‘over filling’ of the cells of water treatment apparatus. | 07-23-2009 |
Paul Emery, Leeds GB
| Patent application number | Description | Published |
|---|---|---|
| 20100260721 | Enrichment of Cells - The present invention relates to methods of isolating and enriching mesenchymal stem cells (MSCs) comprising treating a tissue sample comprising cells and extracellular matrix with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium and then isolating a fraction of the medium containing MSCs. The isolated MSCs can be isolated in surprisingly large numbers such that the fraction can have immediate use in a number of clinical contexts. This represents an advance of prior art techniques that either require the pooling of large volumes of sample tissues from different sources or require MSCs to be expanded in culture. The invention therefore further concerns the clinical use of cells isolated according to the methods of the first aspect of the invention. | 10-14-2010 |
Ralph Emery, Bridgnorth GB
| Patent application number | Description | Published |
|---|---|---|
| 20090047094 | Tolerance compensating fastener - A tolerance compensating fastener comprising a first member having a first member bore and an outer surface having threads, a second member having a second member bore and a spherical portion engaged with the first member, a third member having threads and disposed through the first member bore and the second member bore, the third member threads engagable with a first mounting portion, a fourth member engaged between the first member and the third member, the fourth member transmits a torque from the third member to the first member whereby the first member is rotated from a second mounting portion toward the first mounting portion, and the second member disposed between the first member and the first mounting portion. | 02-19-2009 |
Stephen Charles Emery, Cheshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20080267971 | Antibodies Directed to Angiopoietin-2 and Uses Thereof - Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies. | 10-30-2008 |
Stephen Charles Emery, Macclesfield GB
| Patent application number | Description | Published |
|---|---|---|
| 20090123474 | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER - The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists. | 05-14-2009 |
| 20090123476 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 05-14-2009 |
| 20110097321 | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER - The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists. | 04-28-2011 |
Stephen Charles Emery, Winterly Cheshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20120108797 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determine regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 05-03-2012 |